A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy.
Saved in:
| Title: | A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy. |
|---|---|
| Authors: | Weiss SA; Yale University School of Medicine, New Haven, Connecticut., Sznol M; Yale University School of Medicine, New Haven, Connecticut., Shaheen M; University of Arizona Cancer Center, Tucson, Arizona., Berciano-Guerrero MÁ; Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain., Couselo EM; Vall d'Hebron University Hospital, Barcelona, Spain., Rodríguez-Abreu D; Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain., Boni V; START Madrid-CIOCC, Hospital Universitario HM Sanchinarro, Madrid, Spain., Schuchter LM; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Gonzalez-Cao M; Instituto Oncológico, Quirón Dexeus University Hospital, Barcelona, Spain., Arance A; Hospital Clínic Barcelona, Barcelona, Spain., Wei W; Yale University School of Medicine, New Haven, Connecticut., Ganti AK; VA Nebraska Western Iowa Healthcare System and University of Nebraska Medical Center, Omaha, Nebraska., Hauke RJ; Nebraska Cancer Specialists, Omaha, Nebraska., Berrocal A; University General Hospital of Valencia, Valencia, Spain., Iannotti NO; Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida., Hsu FJ; Apexigen America, Inc., San Carlos, California., Kluger HM; Yale University School of Medicine, New Haven, Connecticut. |
| Source: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Jan 05; Vol. 30 (1), pp. 74-81. |
| Publication Type: | Clinical Trial, Phase II; Multicenter Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
